MB076: A Potent β-Lactamase Inhibitor for Drug-Resistant Infections

A next-generation β-lactamase inhibitor that restores cefepime's effectiveness against resistant gram-negative bacteria

Background

Multidrug-resistant gram-negative pathogens, particularly Klebsiella pneumoniae producing KPC enzymes, render many β-lactam antibiotics ineffective. Existing β-lactamase inhibitors (BLIS) often suffer from poor solubility, limited spectrum, and suboptimal pharmacokinetics, leading to treatment failure and increased toxicity.

These challenges highlight the urgent demand for more robust and targeted therapies capable of outmaneuvering increasingly sophisticated resistance mechanisms.

Technology

MB076 is a boronic acid transition state inhibitor (BATSI) that restores the activity of cefepime and other β-lactam antibiotics against resistant Enterobacterales. It features an α-amidomethaneboronic acid core with tailored substituents for improved solubility, plasma stability, and pharmacokinetics. MB076: - Inhibits class A and C β-lactamases (e.g., KPC-2, KPC-3, PDC-3). - Demonstrates synergy with cefepime in vitro and in vivo, including 100% survival in murine bloodstream infection models. - Shows linear pharmacokinetics up to 50 mg/kg IV, with a ~3-hour half-life and low clearance. - Enables effective treatment of drug-resistant UTIs, hospital-acquired pneumonia, and bloodstream infections. - Supports step-down therapy and outpatient use, reducing hospital costs. - Is well-tolerated in mice at doses up to 100 mg/kg IV, with no acute toxicity.

Benefits

  • Restores effectiveness of β-lactam antibiotics like cefepime against multidrug-resistant Gram-negative bacteria.
  • Improved solubility and stability in the MB076 derivative enhance pharmacokinetic properties.
  • Demonstrates significant in vitro synergy, achieving substantial bacterial density reduction in time-kill assays.
  • Shows favorable pharmacokinetics including low clearance and a half-life of nearly three hours in animal models.
  • Combination therapy with MB076 and cefepime significantly improves bacterial clearance and survival in infected mice.
  • Effective against β-lactamase-producing resistant bacterial strains, converting resistant isolates to susceptible.
  • Versatile administration routes including oral, parenteral, and topical options.

Applications

  • Treatment of multidrug-resistant infections
  • Hospital-acquired infection management
  • Companion therapy for cefepime
  • Pharmaceutical development for Gram-negatives

Additional info

US and European Patents Pending (18/548,766 & 22763977.0)

Further Details:

Rojas, L. J., et al. (2025). Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030. Antimicrobial agents and chemotherapy, _69_(3), e0096424. https://doi.org/10.1128/aac.00964-24

CWRU-4237